NASDAQ OMX

Partners Justin Watts and Matthew Shade Bolster WilmerHale's IP Litigation Practice in London

Dela

LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- WilmerHale today announced that Justin Watts, PhD, and Matthew Shade, PhD, have joined the firm as partners in its London office, strengthening WilmerHale's position as a firm of choice for complex patent litigation in the United Kingdom and for clients seeking an effective global strategy for their intellectual property disputes.

Dr. Watts, a first-chair patent litigator with deep experience in international disputes including competition matters, and Dr. Shade, a skilled practitioner and former patent examiner in the European Patent Office, come to WilmerHale from a Magic Circle firm, where Dr. Watts was the head of the firm's UK IP litigation practice. Together they bring more than 30 years of combined practice, with experience in a wide range of technologies, including cell phones, pharmaceutical products, semiconductors and aero engines."

"Justin and Matthew are an impressive duo who will substantially strengthen our international patent litigation capabilities," said Susan Murley, co-managing partner of WilmerHale. "Their experience with high-stakes IP litigation work and ability to manage complex international patent disputes will benefit our life sciences and tech clients alike."

"The opportunity to join WilmerHale allows us to be a part of a firm that boasts the most esteemed IP litigation practice in the United States," said Dr. Watts. "Matthew and I are looking forward to joining the WilmerHale team and contributing our UK and EU expertise to extend the ways in which clients can rely upon WilmerHale for well-coordinated and comprehensive guidance in global patent litigation matters."

WilmerHale's IP Litigation Practice features a premier litigation team backed by the academic and industry experience of more than 100 lawyers and technology specialists with scientific or technical degrees. WilmerHale's lawyers have tried major cases in US federal district courts from coast to coast, before the US International Trade Commission, and in Germany and the United Kingdom. The firm's lawyers also regularly represent clients in patent appeals before the US Supreme Court and the Federal Circuit. Since the first year the title of IP Litigation Department of the Year was awarded in 2004, The American Lawyer has honored WilmerHale twice and a finalist six times in this biennial contest. 

Mark Selwyn, co-chair of WilmerHale's IP Litigation Practice, added, "It is with great pride that we welcome Justin and Matthew. They bring a superb track record of success and commitment to legal excellence, and they will further enhance our ability to offer clients the finest representation for their global IP litigation disputes." 

Biographical Information

Dr. Justin Watts

Justin Watts, a patent litigator, was most recently a partner in the IP and information technology practices of a Magic Circle firm, where he was the head of the firm's UK IP litigation practice. Dr. Watts has handled complex, multinational disputes, often involving the intersection of antitrust and intellectual property. He has appeared before UK courts and high courts of Northern Ireland and Singapore, and has coordinated international patent litigation in the US, Germany and the Netherlands. His clients span a range of industries from pharmaceutical and medical device to technology, media and communications.

Dr. Watts is a highly regarded practitioner, earning consistent recognition by industry publications such as Chambers UK and The Legal 500 UK, by which he has been cited as "one of the best and most strategic litigators in the field."

Before his legal career began in 1994, Dr. Watts worked in satellite communications engineering. He earned his BA in electrical sciences and his PhD in optoelectronics from the University of Cambridge, and his diploma in IP law and practice, with commendation, from the University of Bristol.

Dr. Matthew Shade

Matthew Shade was most recently a patent litigator at a Magic Circle firm, where he was a member of the firm's intellectual property and information technology practices since 2007. His work focuses on complex multijurisdictional patent cases, and he often deals with the interface of intellectual property and antitrust law. Dr. Shade has practiced before the English courts and the European Patent Office. His clients span industries from pharmaceuticals and medical devices to consumer electronics.

Previously, Dr. Shade managed the patent department of a high-tech spin-out from Cambridge University and he was a patent examiner at the European Patent Office. He earned his BS, with honors, from the University of Manchester, and his PhD in chemistry from the University of Oxford. He is a registered solicitor in England and Wales and a European patent attorney.

About Wilmer Cutler Pickering Hale and Dorr LLP

WilmerHale provides legal representation across a comprehensive range of practice areas that are critical to the success of its clients. The law firm's leading Intellectual Property, Litigation/Controversy, Regulatory and Government Affairs, Securities and Transactional Departments participate in some of the highest-profile legal and policy matters. With a staunch commitment to public service, the firm is renowned as a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia. For more information, please visit www.wilmerhale.com.

Lauren C. Bishop
WilmerHale
lauren.bishop@wilmerhale.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: WilmerHale via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Stillfront Group AB: Stillfront one of Sweden's fastest growing companies19.10.2017 11:00Pressmeddelande

PRESS RELEASE   October 19, 2017   Stillfront included in Deloitte Sweden Technology Fast 50  Stillfront has been included in Deloitte Sweden Technology Fast 50. Deloitte Sweden Technology Fast 50 is a ranking of Sweden's 50 fastest growing technology companies, based on revenue growth over the last four years. The ranking includes public and private companies, large and small, in all areas of technology, from internet specialists to biotech, digital media technology to life sciences, computers to semiconductors and software to telecommunications. Please find more detailed information (in Swedish) on www.deloitte.se/fast50. Stillfront has since the IPO in the autumn of 2015 recorded a continuous high and profitable growth in revenues rolling 12 months. Since the IPO, Stillfront has increased the number of so-called core products (i.e. games that have more than 5 MSEK in annual revenue rate) from four to fourteen and the number of studi

Stillfront Group AB: Stillfront ett av Sveriges snabbast växande teknikföretag19.10.2017 11:00Pressmeddelande

PRESSMEDDELANDE   2017-10-19   Stillfront med i Deloitte Sweden Technology Fast 50 Stillfront har kommit med i Deloitte Sweden Technology Fast 50 2017. Deloitte Sweden Technology Fast 50 är en ranking av Sveriges 50 snabbast växande teknologiföretag, baserat på tillväxten i nettoomsättningen de senaste fyra åren. Rankingen inkluderar såväl publika som privata bolag och omfattar all typ av teknologi, från mjuk- och hårdvara till life science, kommunikation och clean technology. Mer information finns på: www.deloitte.se/fast50. Stillfront har sedan noteringen hösten 2015 varje kvartal uppvisat en kontinuerlig hög och lönsam intäktstillväxt rullande 12 månader. Stillfront har sedan noteringen ökat antalet så kallade kärnprodukter (dvs spel som omsätter mer än 5 MSEK i årstakt) från fyra till fjorton och antalet studios har ökat från fyra till åtta. "Stillfront har åtnjutit en enastående tillväxt de senaste åren. Vår tillväxt bygger på vår s

Payvision's annual report reveals cross-border ecommerce trends in 201719.10.2017 09:00Pressmeddelande

With online marketplaces and consumer technology leading the way for growth AMSTERDAM, The Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Payvision, global acquirer and data-driven omnichannel solutions provider, has published the findings of its fifth annual cross-border ecommerce research report, in collaboration with Juniper Research. The paper includes the results of a global survey of various industry players regarding the game-changers, the biggest challenges, the best practices for going cross-border, and much more. When compared to last year's findings, the report reveals a new and exciting context for global cross-border trade. The compound annual growth rate predicted for the next three years for cross-border ecommerce is now 17%, whereas it stands at just 12% for ecommerce overall. Also, over the past 12 months, merchants' attitudes towards cross-border ecommerce have become more positive, with 50% of respondents agreeing and 31% strongly

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds19.10.2017 08:00Pressmeddelande

Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, announced today the publication of the initial results from a landmark survey into the clinical, social and economic consequences of Dravet syndrome on children, young adults and their families in Developmental Medicine & Child Neurology [doi:10.1111/dmcn.13591]. This study was led by Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53Pressmeddelande

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc

Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42Pressmeddelande

NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum